Karsinoma Sel Basal

01Pathophysiology

BCC originates from the basal layer of the epidermis, arising from stem cells in the interfollicular epidermis and the hair follicle infundibulum rather than the hair bulge as previously believed. It is the most common non-melanoma skin cancer and the most common malignancy overall in humans.

The central molecular driver is aberrant activation of the Hedgehog (Hh) signaling pathway. Under normal conditions, the transmembrane protein Patched-1 (PTCH1) tonically inhibits Smoothened (SMO), keeping the pathway silent. When PTCH1 undergoes a loss-of-function mutation, SMO becomes constitutively active, leading to unregulated nuclear translocation of GLI transcription factors. This drives unchecked proliferation of basal keratinocytes. UV radiation is the primary mutagen responsible for PTCH1 inactivation, which explains why BCC overwhelmingly occurs on chronically sun-exposed skin.

Despite being classified as a malignant neoplasm, BCC is locally invasive but rarely metastasizes (estimated metastatic rate below 0.5%). The clinical behavior is one of slow, relentless local tissue destruction. This is why the term "rodent ulcer" (ulcus rodens) exists: the tumor "gnaws" through tissue over time. Morfeaform and infiltrative subtypes carry a higher risk of subclinical extension and perineural invasion, making margin assessment more difficult.

The connection between pathophysiology and presentation is direct: the pearly, translucent quality of the papule reflects the basaloid cell clusters beneath a thin epidermis, while the arborizing telangiectasia results from tumor-associated angiogenesis. Central ulceration occurs when the tumor outgrows its blood supply.

02Classification and Clinical Manifestation

EADO Classification and Staging

The European Association of Dermato-Oncology (EADO) classifies BCC by increasing difficulty-to-treat and recurrence risk:

03Diagnostic Workup

Dermoscopy is the best initial step when evaluating a suspicious skin lesion. The hallmark dermoscopic finding for nodular BCC is arborizing (tree-like branching) vessels, which are large-diameter focused vessels with multiple branching ramifications. Blue-grey globules and ovoid nests suggest nests of basaloid cells within the dermis. Leaf-like structures and spoke-wheel patterns are more characteristic of pigmented BCC. For superficial BCC, look for short fine telangiectasias, concentric structures, and multiple small erosions.

Histopathology via biopsy is the confirmatory test and is indicated for any lesion where clinical and dermoscopic assessment alone cannot establish the diagnosis. It is also required for lesions in high-risk zones (central face around the eyes, nose, ears, and mouth), large lesions, ulcerated lesions, and cases where subtype identification is needed to guide therapy. The classic histologic picture shows clusters of basaloid cells with peripheral palisading surrounded by a fibromyxoid stroma with characteristic retraction artifact (clefting between tumor nests and stroma). Apoptotic tumor cells, melanocyte colonization, and stromal amyloid deposition may also be present.

Immunohistochemistry becomes relevant when the histologic differential includes trichoepithelioma (a benign follicular tumor that closely mimics BCC). The key discriminator is that BCC expresses BCL2 and CD10 diffusely on tumor cells, while trichoepithelioma expresses CK15, CK20, and podoplanin at the tumor periphery. To differentiate BCC from SCC, BerEP4 is positive in BCC and negative in SCC, while EMA shows the reverse pattern.

04Management and Treatment

Pharmacologic Therapy

Surgical and Procedural Therapy

First-line treatment for most BCC is standard surgical excision with predetermined margins. For low-risk BCC, margins of 3 to 4 mm are adequate. For high-risk BCC (large size, aggressive subtypes like morpheaform, location in the H-zone of the face), margins of at least 5 mm are recommended. Excision is more effective than both radiotherapy and PDT with 5-ALA for nodular BCC.

Mohs micrographic surgery is the preferred approach for high-risk lesions: recurrent BCC, aggressive histologic subtypes, tumors in cosmetically or functionally critical areas (periorbital, nasal, auricular), and lesions with clinically ill-defined borders. Mohs provides real-time, complete margin assessment through horizontal frozen sections, achieving a 2% recurrence rate at 30 months compared to 3% for standard excision. The tradeoff is that Mohs is more resource-intensive and costly.

Destructive techniques like electrodesiccation and curettage (ED&C), cryosurgery, and CO2 laser ablation are appropriate only for small, well-defined, low-risk BCCs. A notable limitation of CO2 laser ablation is that it destroys the tissue, making subsequent histopathologic evaluation impossible.

Photodynamic therapy (PDT) with aminolevulinic acid (ALA) or methyl aminolevulinate (MAL) is an option for superficial BCC and low-risk nodular BCC. While PDT provides a better cosmetic result than excision (particularly MAL-PDT), it is less effective at tumor clearance for nodular subtypes.

Hedgehog pathway inhibitors (vismodegib, sonidegib) represent the systemic therapy option for locally advanced BCC that is not amenable to surgery or radiotherapy, and for the rare metastatic BCC. These drugs work by inhibiting SMO, directly targeting the molecular driver of the disease. Side effects include muscle spasms, dysgeusia, alopecia, and weight loss.

Topical imiquimod (a toll-like receptor 7 agonist that stimulates local immune response) is used for small superficial and nodular BCC, though it carries a lower cure rate compared to surgery. Topical 5-FU is another option limited to superficial BCC.

Consultation

Radiotherapy referral is indicated when radiation is the chosen treatment modality. Hematology-Oncology referral is appropriate for cases requiring systemic chemotherapy or Hedgehog inhibitor therapy.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students get BCC questions wrong is by confusing the subtype with the management approach. The vignette may describe a scar-like, ill-defined, whitish plaque on the nose, and the student selects standard excision with 3-4 mm margins. This is wrong because the description points to morpheaform BCC in a high-risk location, which requires either Mohs micrographic surgery or wide excision with at least 5 mm margins. The test is checking whether you can match the clinical subtype and anatomic location to the appropriate surgical strategy.

Another common trap involves superficial BCC mimicking benign dermatoses. The vignette gives a persistent, non-healing, erythematous scaly patch on the trunk that "has not responded to topical steroids." Students pick eczema or psoriasis. The key discriminator is the lack of response to standard dermatitis treatment plus unilateral distribution, which should trigger biopsy.

For pigmented BCC, the trap is selecting melanoma as the diagnosis. The giveaway in the vignette is the presence of arborizing telangiectasia and a pearly quality, which melanoma does not have. Dermoscopy findings in the question stem will often include "tree-like branching vessels" rather than an irregular pigment network.

On treatment questions, remember that Hedgehog inhibitors (vismodegib, sonidegib) are reserved for locally advanced unresectable or metastatic BCC, not for routine cases amenable to surgery. If the vignette describes a patient with a giant, inoperable facial BCC invading bone (Stage IIIC), the answer is a Hedgehog inhibitor, not wider excision.

Finally, do not forget that BCC rarely metastasizes but has a 30-50% chance of developing a second primary lesion within 5 years. Follow-up surveillance at 3 to 12 month intervals (based on risk category) is a tested concept. The prognosis for life (quo ad vitam) is generally favorable (dubia ad bonam), while prognosis for function and cure (quo ad functionam and quo ad sanactionam) are more guarded (dubia ad malam), especially for high-risk subtypes.